{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:03:31Z","timestamp":1769547811063,"version":"3.49.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie, Germany","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MSD, Germany"},{"DOI":"10.13039\/100004319","name":"Pfizer, Germany","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis, Germany","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.berh.2019.01.014","type":"journal-article","created":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T11:14:50Z","timestamp":1550920490000},"page":"472-484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Emerging treatment options for spondyloarthritis"],"prefix":"10.1016","volume":"32","author":[{"given":"Murat","family":"Torgutalp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2019.01.014_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.berh.2019.01.014_bib2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic Arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2019.01.014_bib3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrrheum.2017.56","article-title":"Pathogenesis of ankylosing spondylitis - recent advances and future directions","volume":"13","author":"Ranganathan","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2019.01.014_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/BOR.0000000000000187","article-title":"The intestinal microbiome in spondyloarthritis","volume":"27","author":"Gill","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2019.01.014_bib5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/BOR.0000000000000069","article-title":"The interleukin-23\/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis","volume":"26","author":"Yeremenko","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2019.01.014_bib6","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2019.01.014_bib8","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2019.01.014_bib9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nrrheum.2016.42","article-title":"New evidence on the management of spondyloarthritis","volume":"12","author":"Sieper","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2019.01.014_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1759720X17706454","article-title":"Tumor necrosis factor-alpha (TNFalpha) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy","volume":"9","author":"Rios Rodriguez","year":"2017","journal-title":"Therapeut Adv Musculoskel Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.rdc.2015.07.010","article-title":"Biologic therapy for psoriatic arthritis","volume":"41","author":"Mease","year":"2015","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.berh.2019.01.014_bib13","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13075-017-1350-9","article-title":"Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial","volume":"19","author":"Hartl","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2019.01.014_bib14","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.01.014_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177231","article-title":"Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-alpha inhibitors","volume":"12","author":"Maas","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.berh.2019.01.014_bib17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202641","article-title":"Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials","volume":"73","author":"Goulabchand","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib19","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17a in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2019.01.014_bib20","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2019.01.014_bib21","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/acr.23537","article-title":"Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2-year results from the FUTURE 2 study","volume":"70","author":"Coates","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2019.01.014_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2019.01.014_bib23","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib24","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2019.01.014_bib25","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1002\/art.39805","article-title":"Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a phase III randomized trial (MEASURE 1)","volume":"68","author":"Deodhar","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2019.01.014_bib26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study","volume":"76","author":"Sieper","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2019.01.014_bib28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.berh.2019.01.014_bib29","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib30","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/rheumatology\/kex361","article-title":"What is the best treatment target in axial spondyloarthritis: tumour necrosis factor alpha, interleukin 17, or both?","volume":"57","author":"Poddubnyy","year":"2017","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2019.01.014_bib31","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2019.01.014_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11926-017-0681-5","article-title":"Mechanism of new bone formation in axial spondyloarthritis","volume":"19","author":"Poddubnyy","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.berh.2019.01.014_bib34","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.39008","article-title":"Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis","volume":"67","author":"Mease","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2019.01.014_bib35","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/cmi.2015.105","article-title":"The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity","volume":"13","author":"Song","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.berh.2019.01.014_bib36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"Interleukin-23-Independent IL-17 production regulates intestinal epithelial permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.berh.2019.01.014_bib37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib38","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.berh.2019.01.014_bib39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3899\/jrheum.170429","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1)","volume":"45","author":"van der Heijde","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2019.01.014_bib40","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.berh.2019.01.014_bib41","author":"Deodhar","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2019.01.014_bib42","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/bcp.13185","article-title":"First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis","volume":"83","author":"Glatt","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.berh.2019.01.014_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-eular.7889","article-title":"LB0001-Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"77","author":"van der Heijde","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib45","unstructured":"Bimekizumab demonstrates impressive joint and skin responses for psoriatic arthritis patients. https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/Bimekizumab-demonstrates-impressive-joint-and-skin-responses-for-psoriatic-arthritis-patients-nbsp Last accessed on 16-FEB-2019."},{"key":"10.1016\/j.berh.2019.01.014_bib46","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2019.01.014_bib47","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2019.01.014_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2017.08.024","article-title":"Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials","volume":"78","author":"Lebwohl","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2019.01.014_bib49","unstructured":"LUMICEF\u00ae approved in Japan. https:\/\/www.kyowa-kirin.com\/news_releases\/2016\/pdf\/e20160704_01.pdf. Last accessed on 16-FEB-2019."},{"key":"10.1016\/j.berh.2019.01.014_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-eular.1615","article-title":"Pharmacokinetics, safety and tolerance of BCD-085, a novel IL-17 inhibitor, based on the results of phase 1 clinical study in healthy volunteers","volume":"75","author":"Chernyaeva","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-eular.2380","article-title":"OP0028-Efficacy and safety of bcd-085, a novel il-17 inhibitor, in ankylosing spondylitis. results of phase 2 clinical study","volume":"77","author":"Mazurov","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib52","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib53","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib54","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1136\/annrheumdis-2018-eular.2140","article-title":"OP0307-Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib55","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.berh.2019.01.014_bib56","article-title":"Efficacy and safety results of guselkumab, an anti-IL23 monoclonal antibody, in patients with active psoriatic arthritis over 24 Weeks: a phase 2a, randomized, double-blind, placebo-controlled study","volume":"68","author":"Deodhar","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2019.01.014_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/13543784.11.1.1","article-title":"Update on the therapeutic potential of PDE4 inhibitors","volume":"11","author":"Dyke","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.berh.2019.01.014_bib58","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis","volume":"72","author":"Pathan","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib59","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1136\/ard.2010.145946","article-title":"Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2019.01.014_bib61","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib62","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.berh.2019.01.014_bib63","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.berh.2019.01.014_bib64","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1002\/art.30418","article-title":"Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1beta, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis","volume":"63","author":"Koenders","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.01.014_bib65","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17a-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.01.014_bib66","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/art.40580","article-title":"ABT-122, a bispecific dual variable domain immunoglobulin targeting tumor necrosis factor and interleukin-17a, in patients with rheumatoid arthritis with an inadequate response to methotrexate: a randomized, double-blind study","volume":"70","author":"Genovese","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2019.01.014_bib67","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/rheumatology\/key173","article-title":"Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2019.01.014_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-eular.2564","article-title":"Low dose IL-2 therapy can recovery Th17\/Treg cell balance in patients with ankylosing spondylitis","volume":"76","author":"Xu","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.01.014_bib69","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s10067-016-3202-4","article-title":"The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis","volume":"35","author":"Fishman","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2019.01.014_bib70","first-page":"41","article-title":"Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial","volume":"35","author":"Silverman","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2019.01.014_bib71","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1468-3083.2011.04078.x","article-title":"Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial","volume":"26","author":"David","year":"2012","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"key":"10.1016\/j.berh.2019.01.014_bib72","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2217\/imt-2017-0034","article-title":"Hematopoietic and mesenchymal stem cells: a promising new therapy for spondyloarthritis?","volume":"9","author":"Rios Rodriguez","year":"2017","journal-title":"Immunotherapy"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219300154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219300154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:18:08Z","timestamp":1761499088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694219300154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1521694219300154"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2019.01.014","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging treatment options for spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2019.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}